全文获取类型
收费全文 | 32355篇 |
免费 | 2079篇 |
国内免费 | 259篇 |
专业分类
耳鼻咽喉 | 434篇 |
儿科学 | 591篇 |
妇产科学 | 489篇 |
基础医学 | 3977篇 |
口腔科学 | 1544篇 |
临床医学 | 2659篇 |
内科学 | 8680篇 |
皮肤病学 | 391篇 |
神经病学 | 3300篇 |
特种医学 | 1293篇 |
外科学 | 5225篇 |
综合类 | 93篇 |
一般理论 | 6篇 |
预防医学 | 1312篇 |
眼科学 | 538篇 |
药学 | 1694篇 |
中国医学 | 72篇 |
肿瘤学 | 2395篇 |
出版年
2023年 | 333篇 |
2022年 | 275篇 |
2021年 | 1087篇 |
2020年 | 745篇 |
2019年 | 1022篇 |
2018年 | 1205篇 |
2017年 | 956篇 |
2016年 | 1067篇 |
2015年 | 1130篇 |
2014年 | 1459篇 |
2013年 | 1777篇 |
2012年 | 2776篇 |
2011年 | 2672篇 |
2010年 | 1499篇 |
2009年 | 1363篇 |
2008年 | 2145篇 |
2007年 | 2256篇 |
2006年 | 2029篇 |
2005年 | 1842篇 |
2004年 | 1642篇 |
2003年 | 1493篇 |
2002年 | 1294篇 |
2001年 | 255篇 |
2000年 | 232篇 |
1999年 | 217篇 |
1998年 | 190篇 |
1997年 | 170篇 |
1996年 | 125篇 |
1995年 | 136篇 |
1994年 | 123篇 |
1993年 | 105篇 |
1992年 | 114篇 |
1991年 | 93篇 |
1990年 | 79篇 |
1989年 | 54篇 |
1988年 | 85篇 |
1987年 | 61篇 |
1986年 | 44篇 |
1985年 | 63篇 |
1984年 | 52篇 |
1983年 | 43篇 |
1982年 | 43篇 |
1981年 | 28篇 |
1980年 | 24篇 |
1979年 | 41篇 |
1978年 | 30篇 |
1977年 | 22篇 |
1974年 | 21篇 |
1973年 | 31篇 |
1972年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Cynthia Aristei Valentina Lancellotta Marco Piergentini Giacomo Costantini Simonetta Saldi Sara Chierchini Antonella Cavalli Luca Di Renzo Oscar Fiorucci Massimo Guasticchi Vittorio Bini Alessandro Ricci 《Brachytherapy》2019,18(1):57-62
Purpose
High-dose-rate, multicatheter interstitial brachytherapy is technically complex and operator-dependent, requiring lengthy training and specialized skills. Furthermore, until the advent of contouring on computerized tomography (CT) images, difficulties existed in locating the target volume precisely. The present article reports the results of a study that aimed at producing and validating a 3D-printed template to aid in target volume localization for multicatheter interstitial brachytherapy in patients with breast cancer.Methods and Materials
Thirteen patients, candidates for accelerated partial breast irradiation or boost, were enrolled in the study. The target volume was defined on CT slices, and a template with empty spaces corresponding to the target volume projection on the patient's skin was produced by a 3D printer. The procedure was compared with the standard method followed in our center (1) visually, by assessing overlap between the target volume projections on the patient's skin, (2) by X-ray findings, and (3) by intraclass correlation coefficient.Results
Visual assessment and X-ray findings showed the 3D-printed target volume always fell within the standard volume in all 13 patients. The intraclass correlation coefficient indicated moderate agreement for both the medial and the lateral skin projections.Conclusions
The 3-D printed templates constitute a quick, easy, and reliable method to localize the target volume for high-dose-rate interstitial multicathether brachytherapy in patients with breast cancer and can safely be used in clinical practice. 相似文献32.
33.
Matteo Lambertini Francesca Poggio Marco Bruzzone Benedetta Conte Claudia Bighin Evandro de Azambuja Mario Giuliano Michele De Laurentiis Francesco Cognetti Alessandra Fabi Giancarlo Bisagni Antonio Durando Anna Turletti Ylenia Urracci Ornella Garrone Fabio Puglisi Filippo Montemurro Marcello Ceppi Lucia Del Mastro the GIM investigators 《International journal of cancer. Journal international du cancer》2020,147(1):160-169
Dose-dense adjuvant chemotherapy is standard of care in high-risk early breast cancer patients. However, its role in HER2-positive patients is still uncertain. In this exploratory analysis of the GIM2 trial, we investigated the efficacy of dose-dense chemotherapy in HER2-positive breast cancer patients with or without exposure to trastuzumab. In the GIM2 trial, node-positive early breast cancer patients were randomized to receive four cycles of (fluorouracil)epirubicin/cyclophosphamide followed by four cycles of paclitaxel administered every 2 (dose-dense) or 3 (standard-interval) weeks. After approval of adjuvant trastuzumab, protocol was amended in April 2006 to allow use of trastuzumab for 1 year after chemotherapy completion in HER2-positive patients. The efficacy of dose-dense chemotherapy in terms of disease-free survival (DFS) and overall survival (OS) was assessed according to HER2 status and trastuzumab use. Out of 2,003 breast cancer patients, HER2 status was negative/unknown in 1,551 patients; among the 452 patients with HER2-positive breast cancer, chemotherapy alone or followed by trastuzumab was given to 320 and 132 patients, respectively. Median follow-up was 8.1 years. No significant interaction between HER2 status, trastuzumab use and chemotherapy treatment was observed for both DFS (p = 0.698) and OS (p = 0.708). Nevertheless, there was no apparent benefit in the HER2-positive group treated with trastuzumab (DFS: HR, 0.99; 95% CI 0.52–1.89; OS: HR, 0.95; 95% CI 0.37–2.41). Although dose-dense chemotherapy was associated with a significant survival improvement in high-risk breast cancer patients, its benefit appeared to be smaller (if any) in patients with HER2-positive disease who received adjuvant trastuzumab. 相似文献
34.
Zschoche Marco Emmert Steffen von Bubnoff Nikolas Ranjbar Mahdy Grisanti Salvatore Heindl Ludwig M. Fend Falko Adamietz Irenäus A. Kakkassery Vinodh 《Der Onkologe》2020,26(11):1056-1064
Die Onkologie - Das okuläre Lymphom wird anhand seiner anatomischen Lokalisation in die intraokulären und periokulären Lymphome eingeteilt. Intraokulär kann die Uvea mit ihren... 相似文献
35.
36.
Valeria Cento Claudia Alteri Valentina Mancini Milo Gatti Valentina Lepera Ernestina Mazza Maria Cristina Moioli Marco Merli Jacopo Colombo Carlo Andrea Orcese Alessandra Bielli Stefania Torri Laura Elisa Gasparini Chiara Vismara Andrea De Gasperi Paolo Brioschi Massimo Puoti Roberto Cairoli Gianluigi Lombardi Carlo Federico Perno 《Mycoses》2020,63(12):1299-1310
37.
Marco Matucci-Cerinic Michael Hughes Gloria Taliani Bashar Kahaleh 《Autoimmunity reviews》2021,20(10):102899
ObjectiveTo review similarities between COVID-19 and systemic sclerosis (SSc) early vasculopathy to provide novel insights into both diseases.MethodsA narrative review of the literature supplemented with expert opinion.ResultsThere is clear evidence that the endothelium is at the centre stage in SSc and COVID-19, with endothelial cell activation/injury and dysfunction creating the crucial evolving step in the pathogenesis of both diseases. The angiotensin system has also been implicated in the early stages of both COVID-19 and SSc. Autoptic studies provide novel insights into the effects of SARS-CoV-2 on the endothelium. Normal endothelium and endothelial dysfunction in COVID-19 and SSc are discussed. It is debated whether SARS-CoV-2 infection triggers autoimmunity with production of autoantibodies which is of mechanistic interest because other viral illnesses are potentially involved in endothelial dysfunction and in SSc pathogenesis.ConclusionCOVID-19 is due to a direct assault of SARS-CoV-2 on the vascular system as an acute infection, whereas SSc remains a chronic/sub-acute autoimmune disease of largely unknown etiology Further study and exploration of the SARS-CoV-2 pathogenic mechanisms might provide further useful milestones in the understanding of the early SSc pathogenesis. 相似文献
38.
Willy Baccaglini Felipe A. Glina Cristiano Linck Pazeto Luis G. Medina Fernando Korkes Wanderley M. Bernardo Rene Sotelo Sidney Glina Giancarlo Marra Marco Moschini Xavier Cathelineau Rafael Sanchez-Salas 《Clinical genitourinary cancer》2021,19(1):3-11.e1
This meta-analysis focuses on the accuracy of upgrading to clinically significant prostate cancer (PCa) by multiparametric magnetic resonance imaging-targeted biopsy (MRI-TB) versus systematic biopsy (SB). We searched the Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science, Scopus, and Literatura Latino Americana em Ciências da Saúde databases through January 2020 for comparative, retrospective/prospective, paired-cohort, and randomized clinical trials with paired comparisons. The population consisted of patients with low-risk PCa in active surveillance with at least 1 index lesion on imaging. We evaluated the quality of evidence by using the Quality Assessment of Diagnostic Accuracy Studies-2 score. Group comparisons considered the differences between the area under the curve summary receiver operating characteristic curve in a 2-tailed method. We also compared the positive predictive value of the best single method (MRI-TB or SB) and the referral study test (combined biopsy, a combination of MRI-TB and SB). The meta-analysis included 6 studies enrolling 741 patients. The pooled sensitivity for the 2 groups was 0.79 (95% confidence interval, 0.74-0.83; I2 = 75%) and 0.67 (95% confidence interval, 0.63-0.74; I2 = 55.4%), respectively. The area under the curve for the MRI-TB and SB groups were 0.99 and 0.92 (P < .001), respectively. The positive predictive value for the MRI-TB and combined biopsy groups were similar. The accumulated evidence suggests better results for MRI-TB compared with SB. Therefore, use of MRI-TB alone may be preferable in patients in active surveillance harboring low-risk PCa. 相似文献
39.
Ferdinando Carlo Sasso Pia Clara Pafundi Alfredo Caturano Raffaele Galiero Erica Vetrano Riccardo Nevola Salvatore Petta Anna Ludovica Fracanzani Carmine Coppola Vito Di Marco Antonio Solano Rosa Lombardi Mauro Giordano Antonio Craxi Alessandro Perrella Celestino Sardu Raffaele Marfella Teresa Salvatore Luca Rinaldi 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(8):2345-2353
Background and aimsBeyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort.Methods and resultsIn this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We recorded all CV events occurred during an overall median follow-up of 24 months (IQR 19–34). 770 HCV positive prediabetic patients were enrolled, 398 untreated controls and 372 DAAs treated patients. Overall, the CV events annual incidence was much higher among prediabetic treated patients (1.77 vs. 0.62, p < 0.001), and HCV clearance demonstrated to significantly reduce CV events (RR: 0.411, 95%CI 0.148–1.143; p < 0.001), with an estimated NNT for one additional patient to benefit of 52.1. Moreover, an independent association between a lower rate of CV events and HCV clearance after DAAs was observed (OR 4.67; 95%CI 0.44–53.95; p = 0.016).ConclusionsHCV eradication by DAAs allows a significant reduction of MACEs in the prediabetic population, and therefore represents a primary objective, regardless of the severity of liver disease and CV risk factors. 相似文献
40.
Simona Coco Simona Boccardo Marco Mora Vincenzo Fontana Irene Vanni Carlo Genova Angela Alama Sandra Salvi Maria Giovanna Dal Bello Silvia Bonfiglio Erika Rijavec Claudio Sini Giulia Barletta Federica Biello Franca Carli Zita Cavalieri Giovanni Burrafato Luca Longo Francesco Grossi 《Clinical breast cancer》2021,21(3):218-230.e6
IntroductionBreast cancer survivors are at increased risk of developing unrelated primary cancers, particularly lung cancer. Evidence indicates that sex hormones as well as a deregulation of DNA-repair pathways may contribute to lung cancer onset. We investigated whether the hormone status and expression of markers involved in DNA repair (BRCA1/2, ERCC1, and P53R2), synthesis (TS and RRM1), and cell division (TUBB3) might be linked to lung cancer risk.Patients and MethodsThirty-seven breast cancer survivors with unrelated lung cancer and 84 control subjects comprising women with breast cancer (42/84) or lung cancer (42/84) were enrolled. Immunohistochemistry on tumor tissue was performed. Geometric mean ratio was used to assess the association of marker levels with patient groups.ResultsEstrogen receptor was expressed in approximately 90% of the breast cancer group but was negative in the majority of the lung cancer group, a result similar to the lung cancer control group. Likewise, ER isoform β was weakly expressed in the lung cancer group. Protein analysis of breast cancer versus control had a significantly lower expression of BRCA1, P53R2, and TUBB3. Likewise, a BRCA1 reduction was observed in the lung cancer group concomitant with a BRCA2 increase. Furthermore, BRCA2 and TUBB3 increased in ipsilateral lung cancer in women who had previously received radiotherapy for breast cancer.ConclusionThe decrease of DNA-repair proteins in breast cancer could make these women more susceptible to therapy-related cancer. The increase of BRCA2 and TUBB3 in lung cancer from patients who previously received radiotherapy for breast cancer might reflect a tissue response to exposure to ionizing radiation. 相似文献